[go: up one dir, main page]

IL164095A0 - Treatment of diseases involving defective gap junctional communication - Google Patents

Treatment of diseases involving defective gap junctional communication

Info

Publication number
IL164095A0
IL164095A0 IL16409503A IL16409503A IL164095A0 IL 164095 A0 IL164095 A0 IL 164095A0 IL 16409503 A IL16409503 A IL 16409503A IL 16409503 A IL16409503 A IL 16409503A IL 164095 A0 IL164095 A0 IL 164095A0
Authority
IL
Israel
Prior art keywords
treatment
diseases involving
gap junctional
junctional communication
involving defective
Prior art date
Application number
IL16409503A
Other languages
English (en)
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of IL164095A0 publication Critical patent/IL164095A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • A23G1/48—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds or extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5777—Theobroma, e.g. cocao or cocoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL16409503A 2002-03-21 2003-03-21 Treatment of diseases involving defective gap junctional communication IL164095A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36636302P 2002-03-21 2002-03-21
PCT/US2003/008944 WO2003079998A2 (en) 2002-03-21 2003-03-21 Treatment of diseases involving defective gap junctional communication

Publications (1)

Publication Number Publication Date
IL164095A0 true IL164095A0 (en) 2005-12-18

Family

ID=28454790

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16409503A IL164095A0 (en) 2002-03-21 2003-03-21 Treatment of diseases involving defective gap junctional communication
IL164095A IL164095A (en) 2002-03-21 2004-09-14 Composition for treatment of diseases involving defective gap junctional communication

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL164095A IL164095A (en) 2002-03-21 2004-09-14 Composition for treatment of diseases involving defective gap junctional communication

Country Status (9)

Country Link
US (3) US7514107B2 (xx)
EP (1) EP1494691B1 (xx)
JP (2) JP2005526780A (xx)
CN (1) CN100522157C (xx)
AU (2) AU2003230718B2 (xx)
CA (1) CA2479555C (xx)
IL (2) IL164095A0 (xx)
RU (2) RU2351325C2 (xx)
WO (1) WO2003079998A2 (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507018B2 (en) * 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6733815B2 (en) * 1999-04-16 2004-05-11 Cargill, Incorporated Food ingredient containing wheat gluten, soy grits and soy flour
US20040022916A1 (en) * 2000-12-22 2004-02-05 Atwell William Alan Particulate-based ingredient delivery system
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
KR20050069975A (ko) 2002-07-29 2005-07-05 하와이 바이오테크, 인코포레이티드 질병의 억제 및 완화를 위한 카로티노이드 구조 유사체
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20040131749A1 (en) * 2002-08-29 2004-07-08 Archer-Daniels-Midland Company Phytochemicals from edible bean process streams
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
EP1516625A1 (en) * 2003-09-16 2005-03-23 Institut Pasteur Uses of neuronal channels-forming pannexins for therapy and diagnosis in mammals
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
PL2108270T5 (pl) * 2004-12-08 2016-09-30 Unilever Nv Produkt spożywczy albo napój zawierający teaninę i kofeinę dla zwiększania skupienia umysłu
PL1728434T3 (pl) * 2005-05-31 2009-05-29 Kraft Foods R & D Inc Sposób wytwarzania kompozycji wzbogaconej w polifenol na drodze ekstrakcji łupin kakao
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
ES2281270B1 (es) * 2005-11-30 2008-07-01 La Morella Nuts, S.A. Alimento funcional con efectos positivos en la prevencion de enfermedades cardiovasculares.
US20070207188A1 (en) * 2006-02-16 2007-09-06 Miller Debra L Cocoa products and methods of treating cardiovascular conditions with sugar-free cocoa
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP3744324A1 (en) 2006-06-15 2020-12-02 Mars Incorporated Methods and compositions for improving cognitive function
WO2008011173A2 (en) * 2006-07-21 2008-01-24 Mars, Incorporated Improvement of arginase levels/activity
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1913821A1 (en) * 2006-10-20 2008-04-23 Kraft Foods R & D, Inc. Zweigniederlassung München Polyphenol-rich extract from plant material
GB0719545D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719542D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719544D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
GB0719543D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and novel use thereof
ES2773928T5 (es) * 2008-01-04 2023-06-28 Nestle Sa Composiciones que comprenden ácidos grasos insaturados y compuestos de liberación de óxido nítrico y uso de las mismas para la intensificación de las funciones cognitivas y relacionadas
US20090263518A1 (en) 2008-04-17 2009-10-22 Barry Callebaut Ag Composition and Uses Thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CN102993151B (zh) * 2012-12-17 2014-11-05 云南民族大学 一种黄烷醇类化合物及其制备方法和应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103877144B (zh) * 2013-05-02 2017-02-22 杭州耐奇睿生物医药科技有限公司 花生衣活性组分的应用及包含该花生衣活性组分的组合物
CN103316029A (zh) * 2013-07-17 2013-09-25 张晓明 Polyflavanostilbene A在制备治疗阿尔茨海默病药物中的应用
CN103340888A (zh) * 2013-08-01 2013-10-09 何英 Polyflavanostilbene A在制备治疗缺血性脑损伤药物中的应用
WO2017120033A1 (en) 2016-01-08 2017-07-13 Tufts University Compositions and method for treating and preventing malnutrition
US20170332686A1 (en) * 2016-05-20 2017-11-23 Nestec Sa Mct-based nutrition blend for cardiac protection and treating degenerative mitral valve disease in companion animals
CN107115434A (zh) * 2017-04-07 2017-09-01 贵州神奇老年病研究院 一种治疗老年痴呆的药物及其制作方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
FI65440C (fi) 1981-07-21 1984-05-10 Kaukas Ab Oy Foerfarande foer separering av beta-sitosterol med en laog alfa-sitosterolhalt
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
JPH0231646A (ja) * 1988-07-21 1990-02-01 Daicel Chem Ind Ltd イチョウ抽出物入りチョコレート
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
WO1992019640A1 (en) 1991-05-03 1992-11-12 Raision Margariini Oy A substance for lowering high cholesterol level in serum and a method for preparing the same
DE4325532A1 (de) 1993-07-29 1995-02-02 Schwabe Willmar Präparate aus Crataegus-Arten, Arzneimittel und ihre Verwendung zur Verhinderung des plötzlichen Herztodes sowie von reperfusionsbedingten cardiovaskulären Schädigungen
CN1105194A (zh) * 1994-01-10 1995-07-19 谢锐 茶精及其制造方法
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
US6391310B1 (en) * 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
AU742198B2 (en) * 1996-04-02 2001-12-20 Mars, Incorporated Cocoa extract compounds and methods for making and using the same
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
JPH10245342A (ja) 1997-03-03 1998-09-14 Mitsui Norin Kk β−アミロイド蛋白の神経細胞毒性低減剤
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6264994B1 (en) * 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
US20030017998A1 (en) 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US20020086067A1 (en) * 1999-12-30 2002-07-04 Choi Paula Y. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
US6346280B1 (en) 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
WO1998057545A1 (en) 1997-06-17 1998-12-23 Rutgers, The State University Of New Jersey Hypocholesterolemic compositions from bamboo shoots
DE69827330T2 (de) 1997-08-22 2006-02-02 Unilever N.V. Stanolester enthaltende Zusammensetzung
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
US5932562A (en) 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
AU4891699A (en) 1998-07-20 2000-02-14 Forbes Medi-Tech Inc. Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
US7011856B2 (en) * 1998-08-05 2006-03-14 Amino Up Chemical Co., Ltd. Composition for the treatment of symptoms and conditions associated with aging
US5892068A (en) 1998-08-25 1999-04-06 Mcneil-Ppc, Inc. Preparation of sterol and stanol-esters
WO2000057707A1 (en) 1999-03-15 2000-10-05 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
KR100484328B1 (ko) * 1999-03-17 2005-04-20 모리나가 세이카 가부시키가이샤 코코아 성분을 함유하는 음식물
JP2001048797A (ja) * 1999-08-06 2001-02-20 Ito En Ltd 痴呆症治療経口投与剤
US6207702B1 (en) * 1999-11-17 2001-03-27 Mars, Incorporated Method for reducing postprandial oxidative stress using cocoa procyanidins
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
FR2812873B1 (fr) 2000-08-11 2003-08-01 Barry Callebaut France Procede de production de polyphenols a partir de feves de cacao
DE60120871T2 (de) * 2000-10-13 2007-01-18 NHK Spring Co., Ltd., Yokohama Rückhaltesystem mit Vorrichtung zur Verhinderung des Abtauchens eines Fahrzeuginsassen
NZ544691A (en) 2000-11-03 2007-12-21 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US20020151506A1 (en) * 2000-12-29 2002-10-17 Castillo Gerardo M. Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
NZ528321A (en) * 2001-03-15 2006-09-29 Proteotech Inc Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
WO2002076381A2 (en) 2001-03-15 2002-10-03 Proteotech, Inc. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US20030087937A1 (en) * 2001-10-15 2003-05-08 Nils-Olof Lindberg Nicotine and cocoa powder compositions
WO2003033016A1 (en) * 2001-10-16 2003-04-24 Jenny Phipps Use of neurotrophic factors for treating neurodegenerative diseases and cancer
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
JP2006507357A (ja) * 2002-10-11 2006-03-02 プロテオテック・インコーポレイテッド プロシアニジンｂ２の単離、精製および合成ならびにその使用
EP3744324A1 (en) * 2006-06-15 2020-12-02 Mars Incorporated Methods and compositions for improving cognitive function
WO2008121412A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California Proanthocyanidins from cinnamon and its water soluble extract inhibit tau aggregation

Also Published As

Publication number Publication date
RU2004131193A (ru) 2005-04-10
CA2479555A1 (en) 2003-10-02
CN100522157C (zh) 2009-08-05
US20030180406A1 (en) 2003-09-25
IL164095A (en) 2008-06-05
WO2003079998A2 (en) 2003-10-02
AU2003230718A1 (en) 2003-10-08
RU2351325C2 (ru) 2009-04-10
AU2003230718B2 (en) 2008-09-11
CN1655806A (zh) 2005-08-17
US7514107B2 (en) 2009-04-07
AU2008255187A1 (en) 2009-01-08
WO2003079998A3 (en) 2004-04-01
JP2005526780A (ja) 2005-09-08
EP1494691A2 (en) 2005-01-12
US20090182037A1 (en) 2009-07-16
CA2479555C (en) 2013-02-05
EP1494691B1 (en) 2017-11-01
JP2011088910A (ja) 2011-05-06
US8568805B2 (en) 2013-10-29
EP1494691A4 (en) 2006-03-01
US20140045932A1 (en) 2014-02-13
RU2008147550A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
IL164095A0 (en) Treatment of diseases involving defective gap junctional communication
AU2003301347A8 (en) Methods for monitoring treatment of disease
EG24420A (en) Treatment of ophthalmic conditions
HRP20050163A2 (en) Combination therapy for hyperproliferative diseases
EP1567158A4 (en) METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
AU2003279513A8 (en) Stimulation for treating ear pathologies
GB0302572D0 (en) Method of treatment
AU2003259833A8 (en) Methods of treating neurodegenerative diseases
GB0306309D0 (en) Method of treatment
PL397023A1 (pl) Środek leczniczy do leczenia AIDS
AU2003272247A8 (en) Methods of treating age-related defects and diseases
GB0210741D0 (en) Methods of therapy
GB0208897D0 (en) New method of treatment
GB0217493D0 (en) Novel methods of treatment
AU2002951913A0 (en) Method of treatment
GB0221712D0 (en) Methods of treatment
GB0327975D0 (en) Methods of treatment
GB0213198D0 (en) Method of treatment
AU2003293581A8 (en) Method of identifying therapeutic agents
GB0207091D0 (en) Method of treatment
PT1706094T (pt) Tratamento de condições oftalmológicas
HU0302933D0 (en) Treatment of diseases
GB0215583D0 (en) Method of treatment
GB0226275D0 (en) Method of treatment
GB0221582D0 (en) Method of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted